Media.Player

Anticholinergic adjunct therapy for gastric cancers

總結

This technology is a method for treating gastric cancers by inhibiting the cholinergic receptors that could be combined with existing chemotherapies for an improved treatment regimen.

技術優勢

Readily-available and well-tolerated May increase the effectiveness of current standard-of-care therapies Inexpensive and currently FDA-approved anticholinergic drugs will have minimal effects on cost of treatment

技術應用

Adjuvant treatment for patients with gastric cancer undergoing chemo- and/or radiotherapyPre-symptomatic treatment for patients at high risk of developing gastric cancerNeoadjuvant (pre-surgical) treatment for patients with resectable gastric tumorsAlternative therapy for gastric cancer in place of invasive surgeryResearch tool for examining the molecular biology and cellular pathogenesis of gastric cancerResearch tool for investigating effects of neurotransmitters, innervation, and cholinergic blockade on cancer

詳細技術說明

None

*Abstract

None

*Inquiry

Jerry KokoshkaColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

CU13357

*Principal Investigation

*Publications

Hayakawa Y, Sakitani K, Konishi M, Asfaha S, Niikura R, Tomita H, Renz BW, Tailor Y, Macchini M, Middelhoff M, Jiang Z, Tanaka T, Dubeykovskaya ZA, Kim W, Chen X, Urbanska AM, Nagar K, Westphalen CB, Quante M, Lin CS, Gershon MD, Hara A, Zhao CM, Chen D, Worthley DL, Koike K, Wang TC. “Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling.” Cancer Cell. 2017 Jan 9;31(1):21-34.Zhao CM, Hayakawa Y, Kodama Y, Muthupalani S, Westphalen CB, Andersen GT, Flatberg A, Johannessen H, Friedman RA, Renz BW, Sandvik AK, Beisvag V, Tomita H, Hara A, Quante M, Li Z, Gershon MD, Kaneko K, Fox JG, Wang TC, Chen D. “Denervation reduces gastric tumorogenesis.” Sci Transl Med. 2014 Aug 20;6(250):250ra115.Tech Ventures Reference:IR CU13357Licensing Contact: Jerry Kokoshka

國家/地區

美國